See more : PT Cakra Buana Resources Energi Tbk (CBRE.JK) Income Statement Analysis – Financial Results
Complete financial analysis of Soleno Therapeutics, Inc. (SLNO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Soleno Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- LondonMetric Property Plc (LNSPF) Income Statement Analysis – Financial Results
- Excite Holdings Co., Ltd. (5571.T) Income Statement Analysis – Financial Results
- Rockhaven Resources Ltd. (RKHNF) Income Statement Analysis – Financial Results
- Lumibird SA (0FRI.L) Income Statement Analysis – Financial Results
- ISF Limited (ISFL.BO) Income Statement Analysis – Financial Results
Soleno Therapeutics, Inc. (SLNO)
About Soleno Therapeutics, Inc.
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.55B | 1.45M | 387.56K | 0.00 | 3.00M | 0.00 |
| Cost of Revenue | 1.96M | 2.21M | 2.21M | 2.19M | 2.30M | 1.92M | 1.61M | 1.51M | 352.68K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.96M | -2.21M | -2.21M | -2.19M | -2.30M | -1.92M | -1.55B | -58.52K | 34.87K | 0.00 | 3.00M | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.10% | -4.03% | 9.00% | 0.00% | 100.00% | 0.00% |
| Research & Development | 25.19M | 15.27M | 21.45M | 23.19M | 16.27M | 7.18M | 3.07M | 5.18M | 4.54M | 2.24M | 2.38M | 2.47M |
| General & Administrative | 13.48M | 9.84M | 10.81M | 8.76M | 6.93M | 6.56M | 6.58M | 6.74M | 6.14M | 2.67M | 1.47M | 1.13M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 25.73K | 1.63M | 1.74M | 252.36K | 0.00 | 0.00 |
| SG&A | 13.48M | 9.84M | 10.81M | 8.76M | 6.93M | 6.56M | 6.61M | 8.37M | 7.88M | 2.92M | 1.47M | 1.13M |
| Other Expenses | 2.71M | 0.00 | 0.00 | 4.34M | 289.00K | 6.00K | -585.95K | -100.52K | -183.57K | -4.59M | -1.97K | -22.41K |
| Operating Expenses | 41.38M | 25.11M | 32.26M | 31.95M | 23.20M | 13.73M | 9.68M | 13.55M | 12.19M | 5.16M | 3.85M | 3.60M |
| Cost & Expenses | 41.38M | 25.11M | 32.26M | 31.95M | 23.20M | 13.73M | 9.68M | 15.06M | 12.55M | 5.16M | 3.85M | 3.60M |
| Interest Income | 2.58M | 300.00K | 110.00K | 13.00K | 154.00K | 0.00 | 0.00 | 0.00 | 0.00 | 1.09K | 1.77K | 3.10K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 62.00K | 0.00 | 0.00 | 0.00 | 4.13M | 2.86M | 2.87M |
| Depreciation & Amortization | 1.96M | 2.21M | 2.21M | 2.19M | 2.30M | 1.92M | 1.61M | 19.70K | 108.23K | 28.52K | 42.11K | 43.79K |
| EBITDA | -37.03M | -21.86M | -28.70M | -30.00M | -28.48M | -9.92M | -8.07M | -6.72M | -15.80M | -5.13M | -804.86K | -3.57M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.30% | -1,043.96% | -3,943.82% | 0.00% | -26.83% | 0.00% |
| Operating Income | -41.38M | -24.40M | -31.53M | -36.29M | -23.49M | -14.30M | -12.17M | -13.61M | -12.16M | -5.16M | -846.78K | -3.60M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.78% | -938.12% | -3,137.55% | 0.00% | -28.23% | 0.00% |
| Total Other Income/Expenses | 2.40M | 330.00K | 618.00K | 11.65M | -7.29M | 2.46M | -1.27M | 1.59M | -3.75M | -8.08M | -2.86M | -2.88M |
| Income Before Tax | -38.99M | -24.07M | -30.91M | -24.64M | -30.77M | -11.84M | -13.72M | -12.04M | -15.91M | -13.87M | -3.71M | -6.48M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.88% | -830.14% | -4,104.85% | 0.00% | -123.57% | 0.00% |
| Income Tax Expense | 0.00 | -3.75M | -1.35M | -9.26M | 5.14M | 2.52M | -1.65M | 21.70K | -183.57K | -455.08K | 2.86M | 2.84M |
| Net Income | -38.99M | -20.32M | -29.56M | -15.38M | -35.92M | -13.34M | -15.67M | -12.07M | -15.91M | -13.87M | -3.71M | -6.48M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 1.01% | -831.63% | -4,104.85% | 0.00% | -123.57% | 0.00% |
| EPS | -2.36 | -2.42 | -5.56 | -3.68 | -15.78 | -9.54 | -26.18 | -58.35 | -126.58 | -819.38 | -198.45 | -346.98 |
| EPS Diluted | -2.36 | -2.42 | -5.56 | -3.68 | -15.78 | -9.54 | -26.18 | -58.35 | -126.58 | -819.38 | -198.45 | -346.98 |
| Weighted Avg Shares Out | 16.49M | 8.40M | 5.32M | 4.17M | 2.28M | 1.40M | 598.52K | 206.77K | 125.68K | 16.93K | 18.68K | 18.68K |
| Weighted Avg Shares Out (Dil) | 16.49M | 8.40M | 5.32M | 4.17M | 2.28M | 1.40M | 598.52K | 206.77K | 125.68K | 16.93K | 18.68K | 18.68K |
Why Soleno Therapeutics Stock Ticked Higher on Thursday
An analyst changed his price target on the clinical-stage biotech. He added 10% to his level, which caught the market's attention.
Take Profit: 3 Stocks to Sell That Are Up More Than 200% in 2023
The stock market is ending 2023 with outsized gains. Investors are in a cheerful mood, and many speculative stocks to take profits on are soaring right now.
3 Stock Winners That Are Up 500% or More in 2023
2023 proved to be a wild year, as many investors' top-performing stocks quickly swirled down the drain amid higher interest rates and tightened economic conditions. But, against all odds, the market outlook improved rapidly in early fall before kicking off...
7 Stock Winners That Are Up 1,000% or More in 2023
As you may already suspect, there are not a lot of stocks up 1000% year-to-date, but several stocks trading on major exchanges are up 1000% from their lows set earlier in the calendar year. There are also a few fairly-liquid...
Feeling Lucky? 5 ‘Jackpot' Stocks to Buy for 2024.
This article is an excerpt from the InvestorPlace Digest newsletter. To get news like this delivered straight to your inbox, click here.
Soleno Therapeutics: Impressive Data, But Never Forget Amarin
Soleno Therapeutics has seen a surge in stock value after positive data from Phase III trials of its Diazoxide Choline Extended-Release tablet for Prader-Willi Syndrome. The data showed improvements in body composition and hyperphagia-related behaviors in patients treated with the...
3 Biotech Stocks With Big-Time Breakthrough Potential
In a world in constant evolution and growth, more and more companies are needed that are committed to development and research in the health area. These biotech companies are not only doing the job, but also have potential for future...
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced, as required by Nasdaq Stock Market rules, the grant of...
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
REDWOOD CITY, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update and reported financial results for the third...
Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Long-Term Open-Label Study of DCCR in Prader-Willi Syndrome
One-Year Administration of DCCR in PWS Patients from DESTINY-PWS Demonstrates Significant Improvements in Hyperphagia and Other Behavioral Complications One-Year Administration of DCCR in PWS Patients from DESTINY-PWS Demonstrates Significant Improvements in Hyperphagia and Other Behavioral Complications
Source: https://incomestatements.info
Category: Stock Reports